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Neoadjuvant radio(chemo)therapy is increasingly used in rectal cancer and induces a number of morphologic changes that
affect prognostication after curative surgery, thereby creating new challenges for surgical pathologists, particularly in evaluating
morphologic changes and tumour response to preoperative treatment. Surgical pathologists play an important role in determining
the many facets of rectal carcinoma patient care after neoadjuvant treatment. These range from proper handling of macroscopic
specimens to accurate microscopic evaluation of pathological features associated with patients’ prognosis. This review presents the
well-established pathological prognostic indicators and discusses challenging features in order to provide both surgical pathologists
and treating physicians with a checklist that is useful in a neoadjuvant setting.
1. Introduction
Preoperative radiotherapy with or without chemotherapy
(RCT) followed by total mesorectal excision (TME) has
become a standard treatment for locally advanced rectal
cancers [1–4]. The increasing use of RCT in rectal cancer
creates new challenges for surgical pathologists, particularly
in evaluating morphologic changes and tumour response to
preoperative treatment. Various systems have been suggested
for grading tumour response to RCT [5–10]. However, the
majority of these systems do not consistently correlate with
prognosis [11–14], and their reproducibility is poor [11, 15–
17]. Moreover, RCT alters the macroscopic and microscopic
assessment and prognostic relevance of a fewwell-recognized
pathological features (i.e., tumour and nodal stage, circum-
ferential resection margin, and lymphovascular invasion)
[18–20]. For example, difficulty exists when no remaining
tumours can be identified on macroscopic examination.
In this context, accurate pathological tumour stage (ypT)
depends on how assiduously the pathologists search for resid-
ual tumour, as well as on the number of blocks and slide sec-
tions processed. In addition, RCT may significantly decrease
the number of retrieved lymph nodes [19]. This could
cause underestimation of the nodal status in the absence
of rigorous lymph node search. Controversy also persists
concerning the optimal distal and circumferential margins
[21–28]. Thus, surgical pathologists play an important role
in determining the many facets of rectal carcinoma patient
care after neoadjuvant treatment. These range from proper
handling of macroscopic specimens to accurate microscopic
evaluation of pathological features associated with patients’
prognosis.
The aim of this review is to present the well-established
pathological prognostic indicators and discuss challenging
features, especially those with clinical impact, in order to
provide a checklist that is useful in a neoadjuvant setting, for
both surgical pathologists and treating physicians.
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2. Macroscopic Assessment of TME Specimen
The TME technique is based on the sharp dissection of the
avascular plane between autonomic nerve plexuses and the
mesorectum. This operation results in the excision of the
rectum enveloped by a mesorectal fat column of 2 to 3 cm.
This part of the review presents the methods of assessment
of mesorectum quality, circumferential resection margin
(CRM), distal resection margin, and lymph nodes.
2.1. Evaluation of the Mesorectum. TME specimen handling
begins with assessment of the quality of the mesorectum
(Table 1) [29]. Inspection of the mesorectal surface gives the
first indication of its quality. Full thickness slicing of the
tumour and the mesorectum allows a good assessment of the
adequacy of excision and the regularity of the CRM, which is
the second indicator of the resection quality.
2.2. Specimen Processing. Quirke et al. [29] and Nagtegaal
et al. [30] have developed an approach for the assessment
and processing of the TME specimen. This assessment is
performed by direct visual inspection of the fresh specimen;
the anterior and posterior planes of the mesorectum are
photographed to document their smoothness or irregularity.
Then, the mesorectal fat is inked; care should be taken not
to ink the peritonealized surfaces of the specimen, especially
anteriorly, where the serosa extends lower down, as this
may produce artifact and lead to difficulty in interpreting
serosal involvement by upper rectal tumours that are either
circumferential or anterior in their location [31]. Then, the
specimen is measured and cut open along the anterior aspect
from the top, leaving the bowel intact at a level just above the
peritoneal reflection. After placing loose, formalin-soaked
gauze wicks into the unopened segment of the rectum, the
specimen should be pinned under tension on a corkboard to
minimize shrinkage [32]. After an optimal fixation of at least
72 hours, the unopened segment is sliced transversely at 5mm
intervals in order to identify the area of deepest invasion,
and the slices are photographed again to keep a record of the
quality of the excised mesorectum, the tumour size, localiza-
tion, and distance to all surgicalmargins. Concerning tumour
sampling, the guideline of the Belgian Project on Cancer
of the Rectum (PROCARE; http://www.kankerregister.org/),
which was adapted from Quirke et al. [29] and Nagtegaal
et al. [30], suggests that five initial blocks be taken from
the site of the tumour or suspicious area. In cases with
obvious macroscopic tumour remnant, in addition to taking
the superficial and deepest part of the tumour, sections
showing the closest relationship of tumour to CRM or to
peritoneal surface as well as those containing the transition
from suspicious mesorectal nodules to the CRM should be
taken, as this allows proper evaluation of other pathological
prognostic parameters [33]. When only mucin pools are
found on gross examination, the entire suspicious zone must
be sampled for accurate staging purpose, as residual viable
tumour cells can be present uponmicroscopic examination in
most cases [7]. Obviously, the pathologist should be informed
about the precise location of the tumour before RCT in order
to target tissue sampling effectively.
Recommended method for tumour sampling and exam-
ination in rectal carcinoma following radio(chemo)therapy
and surgery is as follows.
Step 1. Take 5 blocks from the tumour or scarred area
(assuming no obvious tumour was found grossly). These
should include the superficial and deep part of the tumour as
well as the relationship between the tumour and the CRM or
peritoneal surface. If there are anymesorectal nodules, blocks
containing their relation to the CRM should also be taken.
Step 2. If no viable microscopic tumour is identified within
the initial 5 blocks, the entire scarred area should be sampled.
Step 3. If no residual tumour is found after examining
sections from the additional blocks, three levels should be
cut through each block. If no viable tumour cells are present
even after rigorous examination of these sections, complete
pathologic response or ypT0 can be reasonably and reliably
reported.
2.3. Distal Margin. The distal margin, although less impor-
tant than the CRM in terms of frequency of involvement
and impact on recurrence, is still important to assess. There
are two issues to keep in mind when considering the distal
margin: the extent of intramural and extramural continuous
tumour growth and the discontinuous distal mesorectal
spread through lymphatics. In 20% of cases with positive
nodes, there is lymphatic spread distal to the primary tumour.
Furthermore, in many cases these positive distal nodes are
located >2 cm away from the main tumour mass [34]. By
contrast, intramural distal spread >2 cm is seen in only
3.6% of cases [35]. Zhao et al. [36] found that the rate of
discontinuous tumour deposits within the distal mesorectum
was 17.8% and that the extent of distal mesorectal spread
was greater than the extent of intramural spread. From their
data, they concluded that a 1.5 cm distal rectal wall margin
and a 4 cm distal mesorectal margin are necessary to achieve
adequate surgical clearance. Yet, in many cases, distal rectal
wallmargin of≤1 cm also proved to be sufficient in preventing
local recurrence, particularly in tumours limited to the rectal
wall [37, 38].
One final issue to keep in mind, when measuring the
distal margin, is shrinkage artifact. Goldstein et al. [39] have
shown that a 5 cm length of colon and rectum in vivo is
equivalent to 3 cm after resection and 2.2 cm after fixation.
This highlights, once again, the importance of pinning the
specimen on a corkboard to reduce the degree of shrinkage.
2.4. Lymph Node Retrieval. Lymph node status probably
constitutes the singlemost important prognostic determinant
in patients with rectal cancer whether treated preoperatively
or not [40, 41]. International guidelines recommend that at
least 12 lymph nodes are needed for adequate CRC staging
[42, 43]. Nevertheless, there has been evidence suggesting
that preoperative RCT for rectal cancer could reduce lymph
node yield by roughly 33% [19, 44]. Despite this finding, a
high motivation to retrieve as many nodes as possible must
be maintained, since several studies support the concept that
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Table 1: Assessment of the quality of mesorectal excision or completeness of resection∗.
Complete Nearly complete Incomplete
Mesorectum Intact, smooth Moderate bulk, irregular Little bulk
Defects Not deeper than 5mm Unexposed muscularis propria Exposed muscularis propria
Coning No coning Moderate Yes
CRM Smooth, regular Irregular Irregular
CRM, circumferential resection margin.
∗Both the whole fresh specimen and formalin-fixed slices are examined to achieve optimal assessment.
the more the nodes that are examined, the more accurate
the staging. Moreover, the ratio of positive to total nodes
retrieved, the so-calledmetastatic lymph node ratio, has been
shown to be even more significantly associated with local
recurrence and survival [45–47]. A number of adjunctive
methods including alcohol treatment, xylene clearance, and
ether-basedmethods have been developed in order to address
the challenge of lymph node yield, but most of them require
special equipment or the use of noxious volatile compounds
[48–50]. Therefore, in many pathology laboratories, routine
visual inspection, palpation, and dissection are still the
standard of practice for lymph node retrieval, andmeticulous
examination, as well as the enthusiasm of the examiner, is one
of the most important factors in determining the number of
lymph nodes retrieved.
Once again, it is important to stress that the lateral
mesorectal surface closest to the suspect nodes should be
sampled together with the nodes to allow accurate evaluation
of theCRM[33].Thus, the orientation of suspicious perirectal
nodules that are closely related to the CRM should be well
preserved during the cut-up process, while the normally
looking lymph nodes can be harvested in the usual manner,
taking care not to overcount nodes that appear in more than
one slice due to serial transverse slicing.
3. Microscopic Assessment
3.1. Tumour Histological Type. In the pathological reporting
of colorectal cancer (CRC), the internationally accepted
histological classification of colorectal carcinomas proposed
by the World Health Organization [51] (WHO) is recom-
mended by the College of American Pathologists (CAP)
[52]. Based on this classification, the majority of rectal
cancers are adenocarcinomas of no special type. Besides a
few exceptions, histological type has no stage-independent
prognostic significance [52].The exceptions include the non-
gland-forming tumours such as signet-ring cell carcinoma,
small-cell carcinoma, and undifferentiated carcinoma, which
are prognostically unfavorable [53–55], and medullary car-
cinoma, which is prognostically favorable [56]. In contrast
to the findings in a few studies, mainly limited to univariate
analyses, suggesting that mucinous adenocarcinoma may
be an adverse prognostic factor [57–60], larger studies did
not confirm mucinous histology to be a stage-independent
predictor of poor outcome [61–66]. On the other hand,
mucinous carcinoma tends to be prognostically favorable
when associatedwithmicrosatellite instability (MSI) [67–69].
In summary, based on current evidence, it can be con-
cluded that the only histological types of CRC that are
prognostically significant are signet-ring cell and small-cell
carcinoma (poor prognosis) and medullary and MSI-related
mucinous carcinoma (favorable prognosis).
3.2. TumourDifferentiationGrade. In theWHOclassification
[70], grading of colorectal adenocarcinoma is based on the
extent of gland formation.Therefore, the non-gland-forming
histological types (e.g., signet-ring, small-cell, and undiffer-
entiated carcinoma) are always regarded as high-grade or
poorly differentiated tumours. In most cases, however, the
estimation of the degree of glandular formation is subjective,
resulting in interobserver variation, mainly in grading well
and moderately differentiated tumours. The lack of unifor-
mity in histopathological grading is further complicated by
a number of different grading systems without consensus
among pathologists [52, 71–73]. At present, the available data
are insufficient to support one approach over the other, and
the issue remains problematic. Irrespective of the complexity
of the criteria, most systems stratify adenocarcinomas into
four grades:
(i) Grade 1: well differentiated (>95% glandular forma-
tion),
(ii) Grade 2: moderately differentiated (50%–95% glan-
dular formation),
(iii) Grade 3: poorly differentiated (5%–50% glandular
formation),
(iv) Grade 4: undifferentiated (<5% glandular formation).
Nevertheless, the most recent World Health Organization
series on tumours of the digestive system recommends using
the two-tier grading system (low versus high grade) in grad-
ing colorectal cancer [74]. Despite interobserver variation in
assessment and the lack of standardization, histological grade
has been repeatedly shown by multivariate analyses to be
a stage-independent prognostic factor in a nonneoadjuvant
setting [75–77]. After RCT, however, its impact on patient
survival remains debatable [5, 11, 13, 78–80].
3.3. Lymphovascular and Perineural Invasion. Theprognostic
significance of lymphovascular (LVI) and perineural (PNI)
invasion has been suggested and largely confirmed in a
nonneoadjuvant setting [76, 77, 81–84]. Venous invasion has
been demonstrated by numerous multivariate analyses to be
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an independent adverse prognostic factor in CRC [76, 77, 81,
82, 85–87]. In series of studies identifying the exact location of
the involved vessels (i.e., extramural as opposed to intramural
location), it was found that the extramural type was most
predictive of survival [87–89]. In some studies, LVI, without
distinction between venous and lymphatic vessels, has been
found to be prognostically significant [81, 90]. More discor-
dant results have been reported for lymphatic vessel invasion
alone [91, 92]. It is likely that the disparities among existing
studies on vascular invasion are related to inherent problems
in the pathological identification of this feature. Definitive
diagnosis of vascular invasion requires the identification
of tumour within an endothelial-lined channel. However,
this may be difficult when tumour induced vascular fibrosis
or endothelial destruction is present. In addition, fixation
artifact in the tumour may mimic small vessel involvement.
For these reasons, interobserver variation may be substantial
in the interpretation or recognition of vascular invasion.
Additional limitations in the detection of vessel invasion
are related to specimen sampling. For example, it has been
shown that the reproducibility of detection of extramural
venous invasion increases proportionally from 59% with
examination of 2 blocks of tissue at the tumour periphery to
96% with examination of 5 blocks [89, 93, 94]. Other studies
have suggested that taking various types of tissue blocks
such as tangential ones in addition to perpendicular blocks
raises the chances of detecting extramural venous invasion
[94, 95].
Following preoperative RCT, the prognostic significance
of LVI and PNI has been demonstrated in several studies,
mostly by univariate analysis [96–98]. A study by Du et al.
[97] showed that the disease progression of patients with
LVI in irradiated tumours was significantly delayed as com-
pared with that with LVI-positive tumours in nonirradiated
tumours. They suggested that the aggressiveness of those
tumour cells in the blood or lymphatic vessels may have
been significantly weakened by radiotherapy, though they
were not completely eliminated. In this respect, the stage-
independent prognostic impact of LVI and PNI after RCT
needs to be confirmed in larger studies with multivariate
analysis.
3.4. Tumour Deposits (TDs). Tumour deposits (TDs) are dis-
crete adenocarcinoma nodules encountered in the peri-
colonic and perirectal fat during routine histopathological
examination of advanced CRC specimens. Their prevalence
in the mesorectum ranges from 6% to 64% [99–101]. TDs
are histologically heterogeneous and may be associated with
several types of recognizable anatomic structures such as
veins, lymphatic vessels, and nerves, whereas in other cases
carcinoma cells are seen scattered in small aggregates in the
perirectal adipose tissue. This may account for the different
classifications that TDs have undergone over time [102–
104], particularly in the TNM classification series. Table 2
summarizes the major changes in the last four editions of
TNM classification for colorectal cancer.
TheTNM5 introduced the 3mmrule, resulting in a classi-
fication based exclusively on size, independent of histological
features. Accordingly, discontinuous mesorectal tumour cell
aggregates were considered as being primary tumour exten-
sions (pT category) if measured ≤3mm or as lymph node
metastasis (pN category) if >3mm [105].
The TNM6 replaced the size criterion with the shape cri-
terion. Based on this classification, discontinuous mesorectal
tumour nodules were considered as venous invasion if they
have an irregular contour and as regional lymph node
metastasis if they have the shape and smooth contour of a
lymph node [106].
These two classifications have limited value since the TD
classifications are based on a single morphologic criterion
(i.e., size or shape). Moreover, the 3mm rule was based on
unpublished data, which were subsequently not confirmed
[102, 107], and the shape criterion is insufficient to consis-
tently distinguish different types of tumour involvement of
the perivisceral fat [108], being the source of interobserver
variation [107]. In 2009, Puppa et al. [103] proposed a new
categorization of TDs:
(i) vascular-invasion type (extramural venous or lym-
phatic invasion): pT category,
(ii) non-vascular-invasion type (smooth contour, sur-
rounded by lymphocytes, not associated with veins or
nerves): pN category,
(iii) aggressive TDs (scattering pattern, not surrounded by
lymphocytes, having close association with large ves-
sels or neural invasion): pM1a (in-transit metastasis).
TheTNM7 again introduced changes regarding the definition
and classification of TDs. In the last edition, discrete foci of
tumour found in the perivisceral fat or in adjacent mesentery
away from the leading edge of the tumour and showing no
evidence of residual lymph node tissue are considered to be
TDs. If TDs are observed in lesions that would otherwise be
classified as T1 or T2, then the primary tumour classification
is not changed, but the nodule is classified in N1c category
[109].
It seems that the different editions of TNM replace one
subjective definition with another. Moreover, they do not
appear to have prospectively tested this new TD classification
and evaluated its reproducibility, since TNM7 states that a
perivisceral nodule should be recorded as a positive lymph
node if the nodule is considered by the pathologist to be
a totally replaced lymph node (generally having a smooth
contour) [109].
In summary, although the existing classifications of
TDs need further improvement in terms of reproducibility
and prognostic stratification, results from most studies on
patients not receiving preoperative RCT indicated a worse
prognosis for patients with TDs: increased local recurrence
rates, increased development of distant metastases, and
decreased survival [107]. In studies by Ratto et al. [99,
110] who looked at the incidence and prognostic impact of
TDs in rectal cancer specimen after RCT, TDs occurred in
up to 15.40% of cases and their presence was associated
with reduced disease-free and overall survival. In contrast,
Nagtegaal and Quirke [107] and Quirke et al. [111] considered
the presence of TDs as a sign of good response to RCT.
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Table 2: Major changes in the last 4 editions of TNM classification for colorectal cancer.
Edition (year) T category N category M category Stage grouping
4th (1987) — Introducing N3 category — —
5th (1997) — Removing N3 category — —
TDs: introducing the 3mm rule —
6th (2002)
TDs: replacing the 3mm rule with the contour rule — Subdividing stage III intoIIIA, IIIB, and IIICT4 split into T4a and T4b ITC considered as N0
7th (2009)
Changes in TD classification
M1 split into M1a and
M1b
Subdividing stage IV into
IVA and IVB—
Subdividing N1 into N1a,
N1b, and N1c and N2 into
N2a and N2b
ITC, isolated tumour cells.
Whether or not the presence of TDs after RCT is a stage-
independent predictor of poor outcome remains question-
able. In daily practice, the presence of TDs must be included
in the pathology report, specifying their total number, size,
and growth patterns, in order to create more homogeneous
groups of patients for enrolment in clinical trials [112].
3.5. Pathological Stage. Pathological staging following com-
plete resection has long been considered the most powerful
prognostic indicator in CRC [113]. The same holds true in
rectal carcinoma after preoperative RCT [114–116]. Although
a large number of staging systems have been developed for
CRC over the years, the tumour node metastasis (TNM)
staging system of the American Joint Cancer Committee
(AJCC) and International Union Against Cancer (UICC)
is by far the most widely recommended. Table 2 lists the
major changes made in the last four editions [109, 113, 117].
TNM 7th edition received a number of criticisms primarily
for the new classification of TDs which lacks both scientific
evidence and reproducibility [118, 119]. In reporting CRC,
some centers prefer the 5th edition of the TNM classification
to the other editions, mainly because of the reproducibility
in TD classification [118, 120]. For future evaluation of the
prognostic relevance of the changes in TNM classification,
however, the 7th edition should be used, yet the conflicting
feature, that is, TDs, should be reported in detail with
description of their number, size, and growth pattern.
For accurate staging of treated rectal carcinoma, it is
important to keep in mind that when microscopic remnants
of tumour are not found, the scarred area must be entirely
sampled [73, 120]. Moreover, if viable tumour is not present
even after examining sections from the whole scarred area,
three levels should be cut through each block to exclude
residual tumour foci, as suggested in the COREphase II study
[121].
3.6. Acellular Mucin (aMUC). In routine microscopic exam-
ination of neoadjuvantly treated rectal carcinoma specimens,
mucus pools can be encountered in up to one-third of cases
[122, 123]. With regard to this, a few recent studies have
demonstrated that the presence of acellularmucin (aMUC) in
rectal carcinoma after neoadjuvant RCT did not have signif-
icant impact on patient outcome [122, 124, 125]. de Campos-
Lobato et al. looked at the prognostic value of aMUC in
rectal cancer patients achieving ypT0 after preoperative RCT
and concluded that aMUC did not affect local recurrence
but may suggest a more aggressive tumour biology [125].
These findings are in support of the current CAP consensus
statement that acellular mucin pools are not to be regarded
as residual tumour and that their presence is to be recorded
separately from the ypT category [122].
3.7. Local Inflammatory Response. The tumour associated
inflammatory infiltrate has long been considered a type of
host response and an important prognostic factor in rectal
cancer [126, 127]. After preoperative RCT, rectal cancer could
undergo tumour regression by eradication of carcinoma cells
and replacement by fibrous or fibroinflammatory tissues [123,
128, 129]. Nagtegaal et al. [130] and Shia et al. [123] found
that patients with an extensive fibroinflammatory infiltrate
around the tumour had lower recurrence rates. Two recent
studies by Debucquoy et al. [128, 129] showed a better
disease-free survival in rectal cancer patients whose TME
specimens contained fibroinflammatory changes after RCT
(Figure 1). Overall, a marked inflammatory cell component
is not commonly seen in posttreatment rectal tumours
[123, 128, 129]. Shia et al. [123] reported that, in 60% of
cases, the inflammatory infiltration was only minimal. These
findings imply an impaired or inhibited immune function in
patients treated with RCT. Accordingly, it can be suggested
that patients who maintain a more extensive inflammatory
response at the tumour bed after RCT have a better outcome,
and this factor is relevant in assessing the prognosis of these
patients [123, 128, 129].
3.8. Therapy Response Assessment. Response to RCT ranges
from minimal treatment effects to complete eradication of
the primary tumour. Some authors used cellular-response
grading which is based on the amount of residual viable
tumour in relation to stromal fibrosis [5–8, 16, 131], whereas
others looked at stage shift in the treated specimens, including
tumour and nodal downstaging, when assessing response
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Figure 1: Pronounced fibroinflammatory changes after neoadjuvant
RCT.
[11, 132, 133]. To date, none of the cellular-response grading
systems has gained universal acceptance [11, 134], not only
because the majority of them could not consistently predict
patient outcome [11–14] but also because their reproducibility
is poor, particularly for categories defining moderate to
minimal regressive changes [11, 15–17]. On the other hand,
evaluation of downstaging is objective and reproducible.
Moreover, downstaging has been consistently demonstrated
to correlate significantly with improved survival [11, 128, 129,
135]. Nevertheless, no study has investigated the prognostic
impact of both cellular-response grading and downstaging in
the same study cohort. Some studies [14, 136–138] specifically
examined the prognostic impact of pathological complete
response (pCR), defined by the complete absence of viable
tumour cells in the primary tumour site (ypT0). The precise
classification of pCR or ypT0 can be an effort- and time-
consuming task provided that residual viable tumour cells
could be identified in many cases upon rigorous microscopic
examination (i.e., multilevel sectioning of the blocks con-
taining the scarred area) [7, 121]. In this regard, the varying
proportion of pCR observed in previous studies might have
been due to the difference in dissection and examination
methods used in each laboratory. In spite of this variation, the
pCR status has been shown, in a few randomised trials and
other studies, to significantly correlate with decreased local
recurrence rate and improved survival [137–143].
3.9. Circumferential Resection Margin (CRM). On micro-
scopic examination, the distance of the tumour to the CRM
may be the single most critical factor in predicting local
recurrence (LR) after RCT and surgery [13, 29, 37]. The
CRM involvement by tumour also has been shown to predict
distant recurrence and overall survival (OS) in some studies
[27, 144]. Although the definition of positive CRM varies
among studies [27, 28], themajority of them involving several
thousands of patients support the use of 1mm as cut-off
value for involved CRM [27]. The methods on which CRM
measurement is based have been discussed in a study by
Nagtegaal et al. [30] who looked at the difference in LR
rates among cases with positive CRM as measured from
the deepest point of invasion of the primary tumour and
those with positive CRM as measured from invaded lymph
nodes in the perirectal fat. They showed that patients with
a positive CRM due to direct tumour extension developed
local recurrence more frequently than those with a positive
CRM due to positive nodes (22.1% versus 12.4%, 𝑝 = 0.06).
However, in the same study, therewas no difference in the rate
of local recurrence between patients with a positive CRMdue
to positive nodes compared to those with a negative CRM.
As previously described, TDs are a frequent phenomenon
in the mesorectum. Nevertheless, to date, no study has
examined the prognostic relevance of CRM measurement
based on the distance from lateral resection margin to TDs.
Therefore, to allow further investigations on the prognostic
significance of these two new CRM measurement methods
(i.e., based on distance from positive nodes or TDs), it is
recommended that, in cases with positive lymph nodes or
TDs, practicing pathologists keep a record of the distance
from the lateral resection margin to these perirectal tumour
nodules in addition to reporting the classic CRM.
4. Summary and Conclusion
Preoperative RCT induces changes in both gross appearance
of the surgical specimen and its pathological features, which
could have impact on patient management and outcome.
First of all, the assessment of the mesorectum is necessary
as it is an important indicator of the resection quality. Then,
the resected specimen should be sampled and examined
properly, as summarized in Steps 1, 2, and 3, warranting not
leaving out any prognostically relevant samples, particularly
those containing the relationship of the lateral margins
with the primary tumour and mesorectal nodules. Standard-
ized protocols for the grossing of TME specimens should
be available in order for pathologists, pathology residents,
and pathologists’ assistants to handle these specimens in
a uniform and effective manner. Pathological features that
have been consistently reported to significantly influence
patient outcome after RCT include posttreatment pathologi-
cal stage (ypTNM), microscopic status of the CRM, and local
fibroinflammatory response, whereas the stage-independent
prognostic value of histologic grade, LVI, PNI, and TDs
requires further investigation in neoadjuvant setting. Con-
cerning therapy response assessment, downstaging appears
to be better than cellular-response grading in terms of both
reproducibility and clinical outcome prediction.
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